(Albany, US) September 28, 2026 – DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis (NCFB) – Pipeline Insight, 2026” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in the Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline landscape. It covers the NCFB pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NCFB pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the NCFB Treatment Landscape @ https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Report
DelveInsight’s NCFB pipeline report depicts a robust space with 13+ active players working to develop 15+ pipeline therapies for NCFB treatment.
The companies with NCFB drug candidates in the most advanced stage, i.e., Phase III, include Chiesi USA, Inc., Haisco Pharmaceutical Group Co., Ltd., and others.
The leading NCFB companies include Chiesi USA, Inc., Haisco Pharmaceutical Group Co., Ltd., CSL Behring, Sanofi, AATec Medical, Thirty Respiratory, and others.
Promising NCFB pipeline therapies include HSK31858/CHF10196, CSL787, SAR445399, ATL 105, RESP302, and others.
Gain in-depth knowledge of key NCFB clinical trials, emerging drugs, and market opportunities @ Non-Cystic Fibrosis Bronchiectasis (NCFB) Clinical Trials Assessment
Non-Cystic Fibrosis Bronchiectasis (NCFB) Overview
Non-cystic fibrosis (non-CF) bronchiectasis is a progressive respiratory disease characterized by permanent dilation of the bronchi, retention of mucus, and impaired ciliary clearance. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with increased morbidity and worsened quality of life. One of the cornerstones of management is the identification and treatment of underlying causes.
NCFB presents with variable symptoms, ranging from asymptomatic periods to daily manifestations. Common symptoms include chronic cough with mucopurulent sputum, dyspnea, wheezing, and pleuritic chest pain. Physical examination may reveal adventitious breath sounds such as crackles, wheezing, or rhonchi. Exacerbations, marked by changes in sputum production, dyspnea, cough, fever, wheezing, and decreased exercise tolerance, are frequent and define disease progression.
The condition involves irreversible widening and thickening of the medium-sized airways, accompanied by chronic inflammation and bacterial infection. A vicious cycle of excessive bronchial inflammation, bacterial colonization, and recurrent infection leads to progressive destruction of the bronchial walls. NCFB can present in different radiographic patterns, including cylindrical (dilated airways), varicose (focal constrictions), and saccular/cystic (large cyst-like dilations).
Increased recognition of NCFB is likely a result of high-resolution computed tomography (HRCT), which has allowed identification of previously undiagnosed disease. HRCT, which acquires 1-mm thick images of the lung at 10-mm intervals, is considered the gold standard for radiographic diagnosis.
Treatment focuses on managing symptoms, slowing decline in lung function, and preventing exacerbations. Patients are encouraged to make general changes such as smoking cessation. Chest physiotherapy is a well-established treatment with few side effects. Some patients may respond to specialist treatments such as regular antibiotics, often a low-dose macrolide three times a week. Frailty and co-morbidities play a role in deciding the appropriateness of these treatments.
Non-Cystic Fibrosis Bronchiectasis (NCFB) Emerging Drugs Profile
HSK31858/CHF10196: Chiesi USA, Inc./Haisco Pharmaceutical Group Co., Ltd.
HSK31858 (CHF10196) is an investigational oral phosphodiesterase-4 (PDE4) inhibitor being co-developed by Chiesi USA, Inc. and Haisco Pharmaceutical Group Co., Ltd. for the treatment of NCFB. It is designed to reduce chronic airway inflammation by selectively inhibiting the PDE4 enzyme, thereby increasing intracellular cyclic adenosine monophosphate (cAMP) levels in inflammatory cells. Its mechanism of action suppresses the production of pro-inflammatory cytokines and limits the activation and recruitment of neutrophils, helping to reduce airway inflammation, improve lung function, and decrease the frequency of pulmonary exacerbations in patients with NCFB. The drug is currently in the Phase III stage of development for NCFB.
CSL787: CSL Behring
CSL787 is an investigational human plasma-derived immunoglobulin (IgG) inhalation solution administered via a nebulizer. It is designed to deliver immunoglobulin directly to the lungs, with the aim of preventing chronic respiratory tract infections and slowing the progression of chronic lung disease in patients with NCFB. By enhancing local immune defense within the airways, the therapy seeks to reduce recurrent pulmonary exacerbations and improve respiratory health in individuals with impaired airway host defense. The drug is currently in the Phase II stage of development for NCFB.
The Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Report Provides Insights Into
Detailed insights about companies developing therapies for NCFB, with aggregate therapies developed by each company.
Therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for NCFB treatment.
Targeted therapeutics development by NCFB companies, with respective active and inactive (dormant or discontinued) projects.
NCFB drugs under development by stage of development, route of administration, product type, and molecule type.
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and financing details for future advancement of the NCFB market.
Uncover critical updates on therapeutic innovations and their potential impact on patients @ Non-Cystic Fibrosis Bronchiectasis (NCFB) Unmet Needs
Non-Cystic Fibrosis Bronchiectasis (NCFB) Companies
Chiesi USA, Inc., Haisco Pharmaceutical Group Co., Ltd., CSL Behring, Sanofi, AATec Medical, Thirty Respiratory, and others.
The NCFB pipeline report provides the therapeutic assessment of pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
NCFB products have been categorized under various Molecule types such as:
Oligonucleotide
Peptide
Small molecule
Transform your understanding of the NCFB Pipeline! @ Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Drivers and Barriers, and Future Perspectives
Scope of the Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Report
Coverage: Global
NCFB Companies: Chiesi USA, Inc., Haisco Pharmaceutical Group Co., Ltd., CSL Behring, Sanofi, AATec Medical, Thirty Respiratory, and others.
NCFB Pipeline Therapies: HSK31858/CHF10196, CSL787, SAR445399, ATL 105, RESP302, and others.
NCFB Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
NCFB Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Analysis Today! @ Non-Cystic Fibrosis Bronchiectasis (NCFB) Drugs and Companies
Table of Contents
Introduction
Executive Summary
Non-Cystic Fibrosis Bronchiectasis (NCFB): Overview
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Non-Cystic Fibrosis Bronchiectasis (NCFB) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
Inactive Products
Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Companies
Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Products
Non-Cystic Fibrosis Bronchiectasis (NCFB) – Unmet Needs
Non-Cystic Fibrosis Bronchiectasis (NCFB) – Market Drivers and Barriers
Non-Cystic Fibrosis Bronchiectasis (NCFB) – Future Perspectives and Conclusion
Non-Cystic Fibrosis Bronchiectasis (NCFB) Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight
